COVID-19: Diretrizes Médicas II (COVID-19: Guidelines II)

■ Diretrizes para o tratamento farmacológico da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia

Falavigna, Maicon et al.

Rev. bras. ter. intensiva, Jun 2020, vol.32, no.2, p.166-196

https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-507X2020000200166&lng=pt&nrm=iso

■ Recent findings on the coronavírus diseasr 2019 (COVID-19): immunopathogenesis and immunotherapeutics

Negin Ebrahimi, Saeed Aslani, Farhad Babaie et al

Int Immunopharmacol. 2020 Dec; 89: 107082

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547582/

■ Evidence-based management of COVID-19 in cancer patients: guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

Nicola Giesen, Rosanne Sprute, Maria Rüthrich et al

Eur J Cancer. 2020 Nov; 140: 86–104

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505554/

■ Current status of COVID-19 treatment: an opinion review

Sveva Di Franco, Aniello Alfieri, Stephen Petrou et al

World J Virol. 2020 Sep 25; 9(3): 27–37

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520874/

■ Clinical features and radiological manifestations of COVID-19 disease

Pedro Landete, Carlos Andrés Quezada Loaiza, Beatriz Aldave-Orzaiz et al

World J Radiol. 2020 Nov 28; 12(11): 247–26

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745468/

■ SARS-CoV-2 and nervous systema: From pathogenesis to clinical manifestation